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Abstract 
 
Angiogenesis occurs when new blood vessels sprout from pre-existing ones through 
proliferation of endothelial cells (ECs). This process plays a major role in several physiological and 
pathophysiological processes, including atherosclerosis, chronic inflammation and cancer. The tumor-
associated neovasculature is responsible for the supply of nutrients and oxygen, promoting tumor growth 
and metastasis, even though these blood vessels are structurally and functionally abnormal. During 
tumor progression, rapid and uncontrolled proliferation of tumor cells occurs, leading to a hypoxic 
microenvironment with insufficient blood supply. Therefore, tumor cells start to release pro-angiogenic 
factors, such as VEGF (vascular endothelial growth factor), and hypoxia leads to the stabilization of 
HIF-1α (hypoxia-inducible factor 1 α), inducing the expression of genes that will stimulate the formation 
of a new vessel. 
The first objective of this thesis was to unravel the hypoxia effect in metabolic remodeling 
during the endothelial cell activation. An NMR (nuclear magnetic resonance) analysis of HUVECs 
(human umbilical vein endothelial cells) exposed to CoCl2-mimicked hypoxia showed decreased lactate 
and 2-hydroxyisobutyrate extracellular levels in hypoxia. In addition, an increase of intracellular 
formate levels was detected in hypoxia, which suggests a proliferating phenotype due to formate 
involvement in purine synthesis. On the other hand, there was a decrease in the intracellular levels of 
glucose, lactate and acetate upon exposure to hypoxia, precursors of pyruvate. Concerning endothelial 
activation upon hypoxia, an in vitro tube forming assay was performed and indicated a promotion of 
vessel-like structures formation by hypoxia. However, in an ex vivo rat aortic ring assay the exposition 
to CoCl2 resulted in sprouting inhibition. Besides, a wound healing assay demonstrated a migration 
inhibition on cells exposed to CoCl2. This makes us wonder if the concentration of CoCl2 used is actually 
mimicking hypoxia.  
Cysteine (Cys) is an important ROS (reactive oxygen species) scavenger, showed to have an 
involvement in cancer cell remodeling. Since ROS act as pro-angiogenic molecules, we had the intent 
to investigate the effect of Cys in endothelial activation. An aortic ring assay showed a tendency for a 
sprouting increase when exposed to Cys and higher branch points density when exposed to H2O2. 
However, these levels decreased when exposed to Cys and H2O2, what suggests that ROS may play a 
role in inducing angiogenesis, being Cys able to somehow revert this process.  
Many anti-angiogenic strategies were developed over the years, but they have failed mostly 
because the mechanisms involved in neoangiogenesis are not fully understood. Propranolol (a non-
selective β-blocker) has emerged as an effective treatment for infantile hemangiomas, leading to its 
regression. Hence, our second objective was to determine the effect of propranolol in neo-angiogenesis. 
A tube forming assay was performed and showed that propranolol inhibited the formation and destroyed 
the already formed vessel-like structures. Its inhibitory effects extended to migration, without affecting 
cell viability. Besides, an immunofluorescence assay showed that propranolol affected the expression 
of some EC markers, particularly when the exposure was shorter. The effect was also accessed ex vivo, 
in which propranolol inhibited the sprout of endothelial cells from the aortic ring, corroborating the in 
vitro results. 
The metabolic remodeling involved during aortic ring sprouting was also accessed by NMR 
spectroscopy, showing the differential expression of metabolites from different pathways, glycolysis, 
aminoacyl-tRNA biosynthesis, valine, leucine and isoleucine biosynthesis and degradation. 
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This study gives some insights into the metabolic remodeling induced by hypoxia in endothelial 
cells, opening new cues on the metabolic adaptation underlying angiogenesis which, despite being a 
process involving non-cancerous cells it accounts for cancer progression. The results on the effect of 
propranolol in angiogenesis reinforces its use as a therapeutic alternative to target angiogenesis and treat 
cancer not only vascular tumors, being a starting point to further investigations on the mechanisms 
underlying its action.  
 
 
Keywords: Endothelial cells; Angiogenesis; Tumor microenvironment: Hypoxia; Propranolol. 
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Resumo 
 
 A angiogénese ocorre quando novos vasos sanguíneos se formam a partir dos já existentes 
devido à proliferação de células endoteliais (ECs). Estas células que compõem o revestimento do lúmen 
do coração (endocárdio) e dos vasos sanguíneos e linfáticos, têm a capacidade de permanecer 
quiescentes por anos e rapidamente mudar para um estado de ativação em resposta a estímulos. É o 
equilíbrio entre fatores pró e anti-angiogénicos que determina o nível de angiogénese em curso. Quando 
as ECs são estimuladas por fatores pró-angiogénicos, como o VEGF-A (fator de crescimento endotelial 
vascular), há um aumento na proliferação, migração e diferenciação de ECs, levando à formação de um 
novo vaso. A angiogénese desempenha um papel importante em vários processos fisiológicos, como 
durante o reparo de tecidos e o ciclo reprodutivo feminino, sendo também temporariamente ativada em 
processos fisiopatológicos, incluindo aterosclerose, inflamação crónica e cancro. 
Durante a progressão tumoral, ocorre uma proliferação rápida e descontrolada de células 
tumorais, levando a um microambiente hipóxico com fornecimento insuficiente de sangue contendo 
nutrientes e oxigénio. Como tal, as células tumorais começam a libertar fatores pró-angiogénicos. Além 
disso, a hipóxia leva à estabilização do HIF-1α (HIF: fator induzido por hipóxia), que dimeriza com o 
HIF-1β no núcleo e atua como fator de transcrição de genes com elementos responsivos à hipóxia 
(HRE), tal como o VEGF. Portanto, a hipóxia tem um impacto na função das células endoteliais e na 
angiogénese, dado o aumento da taxa glicolítica e a proliferação de ECs devido à indução da expressão 
de genes envolvidos na glicólise. 
Descobertas recentes sugerem que a comunicação entre as células presentes no microambiente 
tumoral é simbiótica, de modo a suportar a remodelação metabólica do tumor. Como tal, há partilha de 
moléculas orgânicas e de sinalização entre os diferentes tipos de células, cooperando para a 
sobrevivência do sistema. Esta relação é ainda mais importante para as células tumorais quando o acesso 
a nutrientes é muito baixo, contribuindo com novas fontes de energia e biomassa. Deste modo, o 
conhecimento das interações metabólicas poderá auxiliar na identificação de novos candidatos a alvos 
terapêuticos para o tratamento do cancro. 
O primeiro objetivo desta tese foi investigar o efeito da hipóxia na remodelação metabólica 
durante a ativação das células endoteliais que poderá ocorrer no microambiente tumoral. Uma análise 
por espetroscopia de ressonância magnética nuclear (RMN) de HUVECs (células endoteliais da veia 
umbilical humana) expostas à hipóxia mimetizada por CoCl2 mostrou níveis reduzidos de lactato em 
hipóxia, tanto intra- quanto extracelulares. No meio extracelular também foi detetado um nível inferior 
de 2-hidroxi-isobutirato em hipóxia em comparação à normóxia, um metabolito associado à via de 
degradação de valina, leucina e isoleucina. Além disso, em hipóxia foi detetado um aumento nos níveis 
de formato intracelular, o que pode indicar um fenótipo proliferativo devido ao envolvimento do formato 
na síntese de purinas. Pelo contrário, houve uma diminuição dos níveis intracelulares de glucose, lactato 
e acetato após exposição à hipóxia. 
Em relação à ativação endotelial após hipóxia, foi realizado um ensaio de tube forming no qual 
HUVECs embutidas em matrigel são estimuladas a formar estruturas semelhantes a vasos, criando uma 
rede que simula o que ocorre in vivo. Assim, as HUVECs foram expostas a normóxia e a CoCl2 para 
mimetizar a hipóxia, observando-se uma estimulação da formação de estruturas semelhantes a vasos por 
hipóxia. No entanto, foi realizado um ensaio ex vivo, o rat aortic ring assay, no qual a exposição a CoCl2 
resultou numa inibição da formação de ramificações de células endoteliais (sprouting) a partir do anel. 
Além disso, um ensaio de wound healing demonstrou inibição da migração em células expostas à 
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hipóxia induzida por CoCl2. Tal faz-nos questionar se as concentrações de CoCl2 utilizadas constituem 
um modelo eficiente para estudo dos efeitos da hipóxia em células ECs. 
A cisteína é um importante scavenger de reactive oxygen species (ROS), estando já 
demonstrado o seu papel na remodelação metabólica de células tumorais. Visto que as ROS atuam como 
moléculas pró-angiogénicas, decidimos investigar o efeito da cisteína na ativação endotelial. Um ensaio 
do aortic ring mostrou uma tendência para um aumento de sprouting quando exposto à cisteína, em 
normóxia e hipóxia, o que vai contra o esperado, visto que a eliminação dos ROS estaria associada a 
uma inibição da angiogénese.  Para assegurar a existência de stress oxidativo, o ensaio foi também 
realizado na presença de H2O2, sendo que este induziu uma maior densidade de branching points 
comparando com o controlo. Porém estes níveis decresceram quando as células foram expostas a cisteína 
e H2O2, o que confirmou que os ROS poderão ter um papel na estimulação da angiogénese, sendo que a 
cisteína é capaz de reverter esse processo. Em relação à migração endotelial, num ensaio de wound 
healing observou-se que nem a cisteína nem o H2O2 afetaram a migração das ECs. Deste modo, é 
necessário verificar o papel da eliminação de ROS na angiogénese, de modo a determinar se uma 
estratégia terapêutica anti-ROS será uma boa aposta para perturbar a angiogénese tumoral. 
Muitas estratégias terapêuticas anti-angiogénicas foram desenvolvidas ao longo dos anos, mas 
falharam principalmente porque os mecanismos envolvidos na neoangiogénese ainda não são totalmente 
compreendidos. Algumas estratégias objetivam a destruição da vasculatura, afetando a sobrevivência 
do tumor. Contudo, ao contrário do que seria pretendido, um microambiente tumoral mais pobre em O2 
(hipóxia) pode servir de estimulo à neoangiogénese. Portanto, o desenvolvimento de novas terapias anti-
angiogénicas eficazes é urgente. 
O propranolol é um β-bloqueador não seletivo, isto é, bloqueia os recetores adrenérgicos β1 e β2 
com igual afinidade. Estes recetores são ativados pela epinefrina e norepinefrina, estando o seu bloqueio 
associado ao tratamento de hipertensão, miocardites, enxaquecas, transtornos de ansiedade e tremores. 
Nos últimos anos o propranolol surgiu como um tratamento para os hemangiomas pediátricos, 
mostrando-se eficaz na regressão destes tumores por vasoconstrição. No entanto, o seu mecanismo de 
ação sobre as ECs e funcionamento dos vasos permanece sob investigação. Assim, o nosso segundo 
objetivo foi estudar o efeito do propranolol na neoangiogénese, uma vez que os β-bloqueadores poderão 
ser uma estratégia potencialmente eficaz para perturbar a angiogénese tumoral. Foi realizado um ensaio 
de tube forming no qual o propranolol inibiu a formação de novas estruturas semelhantes a vasos e 
destruiu as já formadas. Os seus efeitos inibitórios estenderam-se à migração, conforme observado num 
ensaio de wound healing no qual HUVECs foram expostas a este fármaco, na presença e ausência de 
ROS (H2O2). Uma análise de morte celular por citometria de fluxo indicou que o propranolol não afetou 
a viabilidade celular. Além disso, um ensaio de imunofluorescência mostrou que o propranolol afetava 
a expressão de alguns marcadores endoteliais (ICAM, VCAM, CD146, vWF), principalmente em 
tempos de exposição mais curtos. O efeito também foi avaliado ex vivo através de um aortic ring 
sprouting assay, no qual o propranolol inibiu a formação de estruturas a partir do anel, corroborando os 
resultados in vitro. Estes resultados sugerem que o propranolol poderá perturbar a angiogénese in vitro, 
sendo necessários mais estudos de modo a investigar o mecanismo envolvido e qual é o recetor 
adrenérgico, β1 ou β2, responsável pela ativação das vias de sinalização envolvidas na inibição da 
angiogénese. 
A remodelação metabólica envolvida durante o sprouting do anel aórtico também foi avaliada 
por espetroscopia de NMR, mostrando a expressão diferencial de metabolitos de diferentes vias 
metabólicas, incluindo glicólise, biossíntese de purinas, biossíntese e degradação de valina, leucina e 
isoleucina. 
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Este estudo fornece algumas ideias sobre a remodelação metabólica induzida pela hipóxia nas 
ECs, abrindo novas perspetivas sobre a adaptação metabólica subjacente à angiogénese que, apesar de 
ser um processo que envolve células não-malignas, é responsável pela progressão do cancro. Os 
resultados do efeito do propranolol na angiogénese reforçam a sua aplicação como alternativa 
terapêutica anti-angiogénica no tratamento do cancro, não apenas dos tumores vasculares, sendo um 
ponto de partida para novas investigações sobre os mecanismos subjacentes à sua ação. 
   
 
Palavras-chave: Células endoteliais; Angiogénese; Microambiente tumoral; Hipóxia: Propranolol. 
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1. Introduction 
1.1. Cancer biology 
According to the World Health Organization (WHO), cancer is the second leading cause of 
death globally and is estimated to account for 9.6 million deaths in 2018,1 being considered a major 
public health problem. Cancer occurs when there is a malfunction of the mechanisms that maintain 
normal cell proliferation, causing uncontrollable cell division, in a process termed carcinogenesis.2 Such 
impairment in cellular regulation can result from genetic damage that can be caused by tumor-promoting 
chemicals, ionizing radiations, hormones, viruses or even replication errors and spontaneous chemical 
reactions.3 Overall, carcinogenesis has its onset in mutations of three classes of genes: mutations of 
proto-oncogenes that turn them into oncogenes that promote tumor growth; mutations that inactivate 
tumor-suppressor genes, allowing abnormal cell division and survival.2,4 Besides genetics, epigenetic 
modifications can contribute for carcinogenesis by alterations in DNA methylation and in the activity 
of enzymes that modify histones, and consequently chromatin remodeling.3,5   
A tumor is considered malignant when its cells exhibit cell dysplasia (abnormal morphology) 
and in advanced stages are capable of invading and spreading to form metastases (secondary tumors).6 
Tumor progression also depends on the non-neoplastic cells (such as stromal and endothelial cells) 
present in the tumor microenvironment (TME), acting as a network that shares signaling and organic 
molecules.7  
In 2000, Hanahan and Weinberg proposed six biological capabilities and cellular traits that are 
acquired during the development of tumors: sustaining proliferative signaling; evading growth 
suppressors; resisting cell death; enabling replicative immortality; inducing angiogenesis; activating 
invasion and metastasis.8 In 2011 they and others revisited these hallmarks and considered new features: 
genome instability and mutation and tumor-promoting inflammation (considered enabling 
characteristics) and reprogramming energy metabolism and evading immune destruction (two emerging 
hallmarks).7,9 Altogether, the hallmarks were helpful to better understand carcinogenesis, even though 
there is still a lot to learn. 
 
1.2. Mechanisms of formation of new blood vessels 
1.2.1. Vessel formation 
Blood vessels are responsible for the supply of nutrients and oxygen to all tissues in the body, 
in addition to provide immune surveillance. There are several mechanisms that drive the formation of 
blood vessels. During embryogenesis, the assembly of new endothelial cells into a primitive vascular 
plexus is called vasculogenesis.10,11 Additionally, neovasculogenesis occurs in adult when endothelial 
progenitor cells (EPCs) are mobilized from the bone marrow to differentiate into endothelial cells (ECs) 
and start the de novo formation of a vessel.10,12 Vascular mimicry is a phenomenon resembling a vessel 
formation process that is responsible for increased cancer resistance to some therapies. This mechanism 
consists in cancer cells starting to behave as ECs, even co-expressing some ECs markers and being able 
to form structures similar to vessels.10 Nevertheless, when new blood vessels sprout from pre-existing 
blood vessels through proliferation of ECs the process is called angiogenesis. Angiogenesis is 
transiently activated in several physiological processes, such as tissue repair and in the female 
reproductive cycling, and in various pathologies including cancer, atherosclerosis, and chronic 
inflammation.13 
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Angiogenesis is regulated by pro- and anti-angiogenic factors that either induce or inhibit the 
sprouting. Among the positive regulators, VEGF-A (vascular endothelial growth factor-A commonly 
designed solely VEGF) is the most well-studied and it is observed almost ubiquitously at angiogenesis 
sites.14 This growth factor is released by tumor cells and once it binds to its tyrosine kinases receptors 
(VEGFRs) they become activated and dimerize (homo or hetero), triggering an intracellular signaling 
cascade. For example, Ras, Src, and PI3K (phosphatidylinositol kinase) /Akt pathways are activated by 
VEGFR2.15 The VEGF signaling pathway is involved in several steps of angiogenesis, such as ECs 
proliferation, migration, differentiation, tube formation and permeability control, either in physiological 
and pathophysiological conditions.16 
Angiogenesis is a multi-step process. First, vasodilation and an increase of vascular 
permeability occur at the same time of pericytes (supportive mural cells) detachment and then the 
basement membrane that surrounds the capillaries is degraded. This allows the activation of ECs, which 
will proliferate and initiate the formation of the new tube, followed by the formation of the new 
extracellular matrix.10 
ECs constitute the inner lining of blood and lymphatic vessels. In healthy adults, these cells 
have the capacity to remain quiescent for years but rapidly switch to a highly plastic state in response to 
stimuli such as hypoxia (reduced oxygen availability) or growth factors.17,18 There are three subtypes of 
endothelial cells. After a pro-angiogenic stimuli gradient (e.g. VEGF – vascular endothelial growth 
factor), the migratory tip cells become motile (with numerous filopodia) and guide the growing sprout, 
being followed by the stalk cells that proliferate and elongate. Lining the newly established vessel are 
the quiescent phalanx cells, that regulate vascular homeostasis and the barrier function. Mural cells, as 
pericytes, are recruited to stabilize the new connections. These cells share a basement membrane with 
ECs, that needs to be degraded at the beginning of sprouting by matrix metalloproteinases (MMPs).19 
Interestingly, the phenotype of ECs is not genetically predetermined, it is dynamically selected 
in response to cell competition for growth factors, allowing the fittest cell to acquire the tip position. 
The key regulator for this lateral inhibition is VEGF, hence the cells closest to the site with the highest 
VEGF level will be selected as tip cells.18 Upon reaching the tip cell, VEGF binds to its receptor 
VEGFR2, which induces delta-like ligand 4 (Dll4) expression. The neighbor EC binds its Notch receptor 
to Dll4, stimulating the expression of VEGF receptor 1 (VEGFR1) while decreasing VEGFR2 
expression. Ultimately this leads to the increase of VEGFR1/VEGFR2 ratio which lowers the EC 
responsiveness to VEGF, since VEGFR1 has lower affinity to VEGF than VEGFR2, acting as a VEGF 
trap. Consequently, a stalk phenotype is imposed in the latter EC, turning the first in the tip cell, which 
will be able to contact with another tip cell and coalesce, forming the new sprout towards the gradient 
of the growth factor.11,17 
 
1.2.2. Neo-angiogenesis 
During tumor progression an “angiogenic switch” is activated, excessively stimulating 
proliferation and migration of ECs to form new vessels, giving tumor cells better access to nutrients and 
oxygen. As a matter of fact, the relationship between neo-vessels and tumor growth was first proposed 
by Judah Folkman.20 He also suggested a relationship between neo-angiogenesis and the malignancy of 
a tumor,21 since these neo-vessels can be used as routes for neoplastic cells to metastasize.  
Anti-angiogenic strategies consist in the treatment with an angiogenesis inhibitor (e.g. VEGF 
signaling blockade) to stimulate the regression of the vessels and the starvation of tumor cells, leading 
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to tumor regression.17 So far, these strategies have failed, in part because the precise molecular and 
biologic mechanism during cancer neo-angiogenesis still remains unclear. 
The blood vessels formed within tumors are structurally and functionally abnormal. This 
aberrant vasculature is characterized by excessive vessel branching, leakiness, enlarged, distorted and 
tortuous vessels and even mural cells are less abundant.22 These weak ECs junctions will facilitate 
intravasation of cancer cells due to its increased leakiness. Moreover, by destroying the vascular supply, 
anti-angiogenic strategies increase hypoxia within the TME. Consequently, cancer cells adapt and 
acquire a non-oxidative metabolism, depending less on oxygen and increasing its resistance to anti-
angiogenic treatment.23 Due to this dysfunctionality, the efficacy of chemotherapy drug delivery is 
reduced. Therefore, new findings in tumor vessel normalization (by targeting ECs metabolism) could 
improve drug delivery,24 once it partially restores the normal structure of tumor vessels, by improving 
perfusion and tightening the vascular barrier (decreasing leakiness). In combination with chemotherapy 
this could efficiently impair metastasis.22 
 
 
1.3. Cancer metabolism 
1.3.1. Cancer cell metabolism 
Cancer cells have characteristic metabolic alterations necessary for the acquisition of nutrients 
in a nutrient-deficient environment, essential for the production of biomass that will sustain the high 
proliferative rate.25 For instance, cancer cells exhibit high glucose uptake and increased rates of 
glycolysis and lactate production (Warburg Effect), even in the presence of oxygen.23,26 This process is 
usually termed “aerobic glycolysis” and accounts for high lactate concentrations in the TME, which 
becomes more pro-angiogenic. Currently, it is known that aerobic glycolysis is independent of the 
oxidative phosphorylation (OXPHOS) accomplishment.27 Contrarily to Otto Warburg’s hypothesis that 
tumor mitochondria have impaired cellular respiration, in most type of tumors OXPHOS remains 
functional.28 For example, AS-30D tumor cells (hepatoma cells) have a predominantly oxidative type of 
metabolism, being extremely sensitive to OXPHOS inhibitors.29,30  
Glutamine substitutes glucose in all metabolic intercourses.31 Glutamine can be converted into 
glutamate, by the enzymatic action of glutaminase (GLS),32 entering the TCA cycle (tricarboxylic acid 
cycle or Krebs cycle) as α-ketoglutarate, leading to NADPH regeneration and the production of citrate, 
which can be used for the production of acetyl-groups (such as acetyl-CoA) and for fatty acids (FAs) 
synthesis.25,33 
Cysteine (Cys) is a semi-essential amino acid synthesized primarily in the liver and required for 
general protein biosynthesis. Cystine, the oxidized form of Cys, is transported into cell by the xc– 
antiporter system, in exchange for glutamate.34,35 Cystine is rapidly converted to Cys in the intracellular 
milieu, being able to enter in the glutathione (GSH) biosynthetic pathway.34 GSH is a tripeptide 
composed of glutamate, Cys, and glycine that avoids cellular oxidative stress by acting as a free radical 
scavenger and detoxifying agent.36 Increased metabolic activity, mitochondrial dysfunction and 
peroxisome activity are the major sources of reactive oxygen species (ROS) in cancer cells,37 so there is 
a high demand of Cys for GSH synthesis.38 
Since cancer cells are highly proliferative, there is a need for membrane molecules biosynthesis. 
Membrane lipids, such as phospholipids, contain FAs, the “cellular building blocks”.33 In tumors the de 
novo synthesis of FAs takes place in simultaneous with degradation (b-oxidation)39. FAs are also 
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required for energy storage and synthesis of signaling molecules, as well as a source of acetyl-CoA, 
through b-oxidation, to supply OXPHOS.40 
 
1.3.2. Role of tumor microenvironment (TME) in metabolic remodeling 
Apart from the neoplastic cells, in the TME there are endothelial cells, cancer associated 
fibroblasts (CAFs), cancer associated adipocytes (CAA), tumor associated macrophages (TAMs) and 
other immune cells (e.g. B and T cells).41  
Recent findings suggest that the communication between the cells in the TME is symbiotic to 
support tumor metabolism, maintenance, and growth. Therefore in the TME, there are shared organic 
and signaling molecules, produced from different cell types, cooperating and allowing the entire 
system’s survival.41–43 This sharing is even more important to cancer cells when the nutrients levels are 
very low, filling their demands with new sources of energy and biomass. The knowledge about these 
metabolic interactions has the potential to update the list of new cancer therapies candidates.6,44  
 
1.3.3. Endothelial cells (ECs) metabolism 
Normal ECs (i.e., under non-pathological circumstances) rewire their metabolism to meet the 
high demands (energetic and biosynthetic) of the physiological state. ECs resemble cancer cells in their 
preference to use glycolysis rather than OXPHOS when it comes to glucose metabolism.11,22,45 Although 
it seems counterintuitive given the lower ATP production comparing to mitochondrial respiration, this 
will sustain lactate production, which will stimulate angiogenesis.18 Moreover, by abstaining from the 
use of oxygen, ROS are kept in a minimum and high oxygen concentrations are maintained in the blood 
to distribute for the perfused tissues. By using this oxygen-independent pathway, ECs are able to migrate 
through hypoxic environments without major adaptations to their metabolism. This also sustains 
macromolecule synthesis by feeding glycolytic side branches with carbons from glucose. In the case of 
the pentose phosphate pathway (PPP), ribose-5-phosphate is produced and used for the synthesis of 
nucleic acids. This pathway also regulates redox homeostasis, influencing cell viability and 
angiogenesis. This occurs due to the formation of NADPH, which is used in the conversion of oxidized 
glutathione (GSSG) to reduced glutathione (GSH) by GSH reductase. NADPH is also required for the 
synthesis of lipids and nitric oxide (NO).11  
However, if glucose levels decrease significantly, anaerobic glycolysis is impaired (Crabtree 
effect)46 and ECs can switch to OXPHOS metabolism since mitochondria remain functional.47 In 
addition, ECs store glucose as glycogen reserves, probably to have an endogenous source of glucose as 
a backup for energy under glucose-deprived conditions.22,23   
A compartmentalization of glycolytic enzymes (e.g. 6-Phosphofructo-2-Kinase/Fructose-2,6-
Biphosphatase 3 (PFKFB3)) occurs in the filopodia and lamellipodia, the migratory structures of ECs, 
where mitochondria are excluded. This localization is due to an association with F-actin, allowing a 
rapid ATP production (“ATP hot spots”) to fuel actin-myosin contraction and a cytoskeleton remodeling 
during cell migration.11,45 
Similar to cancer cells, glutamate is also the most abundant intracellular amino acid in 
endothelial cells.11 Glutamine contributes to TCA cycle anaplerosis, arginine metabolism and also 
nucleotide synthesis. In addition, OXPHOS is still functioning, producing reducing equivalents to 
sustain ATP production. 
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Comparative to ECs in physiological circumstances, tumor-associated ECs (TECs) have a 
further increased glycolytic flux, evidenced by an increased expression of GLUT1 (glucose transporter) 
and PFKFB317. These cells are hyperproliferative, demanding more substrates for energy production 
and more metabolites for biomass synthesis, being this the reason why they also retain functional 
mitochondria. In fact, TECs are more angiogenic, more responsive to pro-angiogenic signaling, and 
often more resistant to chemotherapeutic and anti-angiogenic drugs. The secretome of cancer cells 
induces responses in TECs, for example cancer cells can stimulate the glucose uptake by TECs and 
cancer cells secrete lactate, which induces EC proliferation.22  
 
1.4. Role of hypoxia in metabolic remodeling in cancer and in neo-angiogenesis 
Hypoxia is a characteristic feature of several pathological conditions, including cancer and 
cardiovascular disease.48 The TME becomes hypoxic due to the insufficient blood supply when rapid 
tumor growth occurs. 
 The hypoxia response occurs through the activation of hypoxia-inducible factors (HIFs), a 
family of transcription factors composed by an oxygen-sensitive subunit (HIF-1α) and a constitutively 
expressed subunit (HIF-1β).49 In normoxia, oxygen binds to oxygen-dependent enzymes, the prolyl 
hydroxylases (PHDs), which hydroxylate two proline residues of HIF-1α on the oxygen-dependent 
domain (ODD).50 This reaction inhibits the dimerization with the HIF-1β subunit, since it promotes 
binding to von Hippel-Lindau tumor suppressor (pVHL), which is part of an E3 ubiquitin ligase 
complex, targeting HIF-1α with ubiquitin for consequent proteasomal degradation.49,51 In contrast, in 
hypoxic conditions the PHDs don’t promote HIF-1α hydroxylation, since the oxygen is missing. Thus 
HIF-1α accumulates, translocate to the nucleus, where dimerizes with HIF-1β forming the heterodimer, 
being the dimerization required for DNA binding. The dimer acts as a functional transcription factor, 
leading to the activation of target genes with specific DNA sequences, named hypoxia-responsive 
elements (HRE).17,52 VEGF expression is induced by hypoxia, since the corresponding gene has an HRE 
region, which will induce ECs proliferation and subsequently neo-angiogenesis.12 
Hypoxia has an impact in ECs function and angiogenesis, hence HIF-1α stabilization induces 
activation of pro-angiogenic genes (VEGF, angiopoietin 1 (ANGPT1), placenta derived growth factor 
(PlGF)), increases the expression of genes involved in glycolysis (e.g. GLUT1, PFKFB3) resulting in a 
higher glycolytic rate and increased ECs proliferation17. Hypoxia leads to higher glycolysis rates by 
upregulation of glycolysis-promoting genes, such as GLUT1, PFKFB3, Lactate dehydrogenase 
(LDHA), Pyruvate dehydrogenase kinase 1 (PDK1). Metabolic pathway analysis of ECs exposed to 
hypoxia indicated increased amino acids biosynthesis, carbon metabolism, promotion of the PPP and 
Cys/methionine metabolism.17 
 
1.5. Role of cysteine in metabolic remodeling in cancer and in neo-angiogenesis 
Recently our team published several papers showing the relevance of thiols (cysteine included) 
in cancer metabolism and therapy escape.53,54 As one of the components of GSH, an important ROS 
scavenger, Cys plays an important role in the maintenance of the redox equilibrium. At non-toxic levels, 
ROS act as pro-angiogenic molecules, being important modulators of endothelial cells. All things 
considered, Cys can be relevant in endothelial activation or, at least, as a ROS scavenger. 
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Hydrogen sulfide (H2S) is synthesized in ECs by three enzymes that degrade Cys: cystathionine-
γ-lyase (CSE), cystathionine-β-synthase (CBS) and by 3-mercapto-pyruvate sulphurtransferase (MpST) 
accompanied by cysteine aminotransferase (CAT). The production of H2S in ECs stimulates 
angiogenesis by promoting ECs repair, proliferation and migration, inhibiting vascular inflammation 
and increasing production of GSH, which decreases oxidative stress.11,55 
However, the role of H2S on cancer is still controversial, once tumors exposed to H2S exhibit 
two opposite behaviors, a pro-cancer and an anti-cancer effect. There are many mechanisms that 
contribute to the pro-cancer effect: induction of angiogenesis; regulation of mitochondrial bioenergetics; 
acceleration of cell cycle progression, and anti-apoptosis function.55,56 Contrarily, H2S can also inhibit 
the cancer cell proliferation through induction of cell cycle arrest, promotion of apoptosis and induction 
of cell injury due to uncontrolled intracellular acidification.55 Therefore, there may be a balance between 
the effects induced by H2S, which depends on each particular cancer cell context. 
 
1.6. β-Adrenergic receptor blockade: an alternative to treat vascular tumors  
Adrenoceptor beta 2 (ADRB2) is the gene that encodes the β2-adrenergic receptor. This cell 
surface receptor is a member of the G protein-coupled receptor superfamily (GPCRs).57 The activation 
of these receptors by epinephrine or norepinephrine,58 leads to the stimulation of adenylate cyclase, that 
results in increased cAMP (cyclic adenosine monophosphate) levels and activation of protein kinase A 
(PKA).59 This may also result in the activation of mitogen activated protein kinase (MAPK) pathway, 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and Akt/protein kinase B.60 
Propranolol is a non-selective β-blocker (which competitively blocks β1 and β2-adrenoceptors 
with equal affinity)61 usually used for the management of hypertension, myocardial infection, migraines, 
anxiety disorders and tremor.62 In the last years, this antagonist has emerged as an effective treatment to 
infantile hemangiomas (IH), since it promotes the regression of these tumors by vasoconstriction,63 
being already FDA approved to IH. These are the most common benign tumors of infancy and involve 
accumulation, proliferation, and differentiation of aberrant vascular structures.63,64 However, its specific 
mechanism(s) of action remain unknown, although there is some knowledge of how propranolol 
interferes with endothelial cells and, thereby, angiogenesis. For example, propranolol induces a 
downregulation of proangiogenic proteins (such as VEGF, bFGF, MMPs) and inhibits the ERK/MAPK 
signaling pathway, thus inhibiting angiogenesis.64,65 The elucidation of the mechanism underlying 
vessels disruption by propranolol, will be a major challenge for the near future, since it can have a 
potential to target angiogenesis and treat cancer. 
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2. Hypothesis and aims 
Our first hypothesis is that endothelial cells undergo a metabolic remodeling to sustain cancer 
angiogenesis, being this process controlled by microenvironment. Therefore, the first objective of this 
thesis is to disclose the influence of hypoxia (an important microenvironmental component) in the 
metabolic remodeling during the endothelial cell activation. 
Our second hypothesis is that β-blockers, such as propranolol, can be a potential cancer therapy 
by disrupting tumor angiogenesis. Accordingly, our second objective is to determine the effect of 
propranolol on bona fide vascularization.  
 
 
3. Materials and Methods 
3.1. Cell Culture 
Human umbilical vein endothelial cells (HUVECs: CRL-1730, ATCC) were used as in vitro 
model of human endothelium for the study of tumor-associated angiogenesis. These cells were cultured 
in Endothelial Cell Growth Basal Medium-2 (EBM-2: CC-3156, Lonza, Bioscience) supplemented with 
EGM-2 SingleQuots Supplements (CC-4176, Lonza, Bioscience): 2% FBS, hydrocortisone, hFGF-B, 
VEGF, R3-IGF-1, ascorbic acid, hEGF, GA-1000 and heparin. The cell culture was maintained at 37°C 
in a humidified environment of 5% CO2. Cells were plated on gelatin-coated T75 flasks (75 cm2) and 
cultured to 75 - 100% optical confluency before they were detached with 0.05% trypsin-EDTA 1X 
(25300-054, Invitrogen) at 37°C for 2 - 3 min. For each assay a Bürker counting chamber was used to 
determine the cell number necessary.  
Cells were exposed to CoCl2 (100 μM; C-8661, Sigma-Aldrich), L-cysteine (Cys; 402 μM; 
102839, Merck), propranolol (100 μM; P8688, Sigma) and H2O2 (15 μM). 
For the NMR assay (3.2), HUVECs were plated in 90 mm cell culture dishes (55 cm2) (2 x 105 
cells/mL) and maintained in EBM-2 all in. The experimental conditions were added on the next day (6h 
incubation). 
For tube forming assay (3.3), cells (1.5 × 105 cells/mL) were plated in 48-well plates and 
exposed to the experimental conditions for 6 h. 
For wound healing assay (3.4), cells (2 × 105 cells/mL) were plated in 24-well plates and 
cultured until reaching a confluent monolayer. After incubation with mitomycin-C to inhibit 
proliferation, the scratch (wound) was made, cells in suspension were removed and adherent cells were 
exposed to the experimental conditions for 24 h. 
For the migration transwell assay (3.5), cells (5 × 105 cells/mL) were plated in the 12 μm 8 μm-
pore inserts. Cells were then exposed to the experimental conditions for 6 h. 
In cell death analysis (3.6), cells (2 × 105 cells/mL) were plated in 24-well plates. After 
starvation (FBS-free culture medium) overnight, cells were exposed to the experimental conditions for 
6h. 
For the immunofluorescence technique (3.7), cells (1.6 × 105 cells/mL) were plated in µ-slide 8 
well. After reaching confluency the experimental conditions were added (6h incubation). 
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3.2. Nuclear magnetic resonance (NMR) for metabolomic detection 
NMR is one of the main techniques used in metabolomics analysis, given the easy sample 
preparation, the ability to quantify the most abundant compounds and its high reproducibility.66 This 
technique is mostly used for untargeted analysis and when allied with isotopically enriched 13C 
molecules allows the tracking of the metabolic pathways that incorporated this isotope.67  
Therefore, NMR assay was performed to identify the effect of hypoxia on endothelial cell 
metabolism. HUVECs were plated in 90 mm cell culture dishes (55 cm2) (2 x 105 cells/mL) and 
maintained in EBM-2 all in. On the next day, cells were treated with 10 mM lactate (20% 13C-lactate 
(sodium 13C-L-lactate; CX1585V; Sigma) + 80% lactate (Sodium lactate; 106522.2500; Merck)), 5 mM 
glucose (G8270, Sigma) and 5 mM glucose (9% 13C-glucose (389374; Sigma-Aldrich) + 91% 12C-
glucose), in the presence and absence of hypoxia (mimicked by 100 μM CoCl2) in Complete Endothelial 
Cell Medium supplemented with VEGF, EGF, L-Glutamine, antibiotic-antimycotic solution and FBS 
from the kit (1168, Cell Biologics). After 6h incubation, the supernatants were collected and stored at   
-20ºC. Cells were harvested with PBS 1X (washed twice), scraped and centrifuged at 155 g for 10 min. 
Methanol and chloroform extraction was performed to separate organic and aqueous phases. Cold 
methanol was added to the cell pellets (4ml methanol/1g cell pellet), followed by water (twice the 
volume of methanol). After a 5 min incubation on ice, chloroform (the same volume of methanol) was 
added to the mixture, followed by water (the same volume of methanol). The samples incubated 10 min 
on ice and were centrifugated at 1700 g for 15 min at 4ºC. Both organic and aqueous phases were 
collected with a glass pipette and stored at -20ºC. The remaining sample preparation was performed at 
ITQB Oeiras. A phosphate buffer with deuterated water (D2O) was added to the aqueous phases. Both 
1H and 13C spectra were acquired in a magnetic field of 500 MHz in UltrashiedTM 500 Plus (Bruker).  
Aortic rings were also analyzed by NMR. After the sprouting assay, the rings were extracted 
from matrigel, washed with PBS 1X and stored at -80ºC. Then we added cold methanol, followed by 
homogenization with a tissue homogenizer. The rest of the extraction was done accordingly to the 
methanol and chloroform extraction mentioned previously. The spectra acquisition was made in a 
magnetic field of 800 MHz in UltrashiedTM 800 Plus (Bruker) at ITQB Oeiras. 
All the spectra analysis was done according to Chenomx NMR suite 8.1 and Human 
Metabolome database (HMDB) in TopSpin 3.2 software. 
 
3.3. Tube-forming assay 
Tube-forming assay is an in vitro experiment that focuses on the angiogenesis stage whereby 
endothelial cells form the vessel sprout, differentiating into vessel-like structures, forming a network 
that simulates what occurs in vivo.68,69 This assay relies on the presuppose that ECs are induced to form 
tube-like structures when cultured on a matrix of basement membrane extract.  
One day prior to assay, the cell medium was replaced by 200 PRF medium (M-200-500, Gibco) 
supplemented with LSGS (S-003-10, Gibco). A 48-well plate was coated with matrigel (354230, 
Corning) and incubated at 37°C for 30 min to solidify. HUVECs were incubated with calcein (C1430, 
Invitrogen), a fluorescent cell permeable dye, for 30 min at 37°C and 5% CO2. 
Cells were harvested and resuspended in a basal medium (200 PRF supplemented with FBS; 
S0615, Thermo Fisher Scientific) or in a pro-angiogenic medium (200 PRF supplemented with LSGS, 
FBS and bFGF) where the experimental conditions were added. Representative images of the tube-like 
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structures formation were acquired at 4 h and 6 h in an Olympus IX53 Inverted Microscope and analyzed 
with ImageJ software (imagej.nih.gov/ij/). 
 
3.4. Wound healing assay 
Wound healing assay is a method to measure the directional 2D cell migration in vitro, used to 
investigate the effect of compounds or genetic manipulation on cell migration.13,70 This assay was 
performed to determine the effect of hypoxia (mimicked by CoCl2), ROS (H2O2) and propranolol (β-
blocker) on ECs cell migration. Cells were plated on gelatin-coated 24-well plates and allowed to form 
a confluent monolayer. Once confluent, cells were incubated for 3 h with mitomycin-C (M4287, Sigma), 
an antimitotic agent that inhibits cell proliferation. A linear scratch in each monolayer was made with a 
P200 pipette tip, creating a gap across the well diameter. The media was replaced to remove debris and 
cells in suspension and to expose cells to the experimental conditions. Bright-field images of each well 
were acquired on the Olympus IX53 Inverted Microscope at the following timepoints: 0, 2, 4, 6 and 24h 
(0, 2, 4, 6, 8, 10 and 24h for experiments with propranolol). Images were analyzed and quantified by 
ImageJ software. 
 
3.5. Transwell migration assay 
Transwells assays (or Boyden chamber assays) are a useful tool to study cell migration and 
invasion.71 To determine the effect of hypoxia and propranolol on migration of ECs in vitro, transwell 
inserts with 8-μm pore size polycarbonate membrane (PI8P01250, Millicell) were used. Cells were 
incubated in FBS free media overnight and the underside of the insert membrane was coated overnight 
at 4ºC with EBM-2 containing 10 µg/ml gelatin (G-1890, Sigma Aldrich). 
Cells were harvested and resuspended in EBM-2 without FBS, while the lower chamber was 
loaded with EBM-2 with FBS and the experimental conditions. Cells incubated at 37°C in a humidified 
environment of 5% CO2 for 6 h. At the end the upper filter membrane was wiped with a cotton swab to 
remove cells that didn’t migrate through the filter to the lower chamber. After washing with PBS 1X, 
cells in the lower surface of the filter were stained with 0.5% (w/v) crystal violet in 25% methanol for 
10 min at room temperature. After washing with 10% methanol, representative images were acquired 
with the Olympus SZX12 Stereozoom Microscope and Olympus IX53 Inverted Microscope. The 
number of cells that migrated through the transwell membrane was assessed using ImageJ software.  
 
3.6. Cell death analysis by flow cytometry 
The cell viability analysis was made by FITC labeled-annexin V/propidium iodide (PI) staining. 
When cells undergo apoptosis the phosphatidylserine (PS) present on the inner surface of the membrane 
translocate to the cell surface. This exposition allows the binding of the labeled annexin V (640906, 
BioLegend) in a calcium-dependent manner.72 To differentiate between early apoptotic cells from 
membrane permeabilized cells (late apoptotic and necrotic cells), we use PI (P4170, SigmaAldrich) that 
is a fluorogenic compound that only binds to double stranded DNA. PI is not permeant to live cells, thus 
staining only membrane permeabilized cells.73 By flow cytometry the percentage of viable, early 
apoptotic, late apoptotic and necrotic cells is assessed. 
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In the context of the present thesis, this assay was performed to analyze the effect of propranolol 
in HUVECs viability. Plated cells were incubated overnight with EBM-2 media without serum (FBS). 
After experimental conditions (6 h incubation), supernatants were collected, cells were harvested with 
trypsin and centrifuged at 155 g for 5 min. Cell pellets incubated with FITC labeled-annexin V in 
annexin V binding buffer 1X at room temperature for 15 min in dark. After incubation, cells were 
resuspended in PBS 1X 0.1% (v/w) BSA and centrifuged at 155 g for 2 min. The remaining pellet was 
resuspended in annexin V binding buffer 1X and PI and analyzed by flow cytometry. FlowJo X v10.0.7 
software was used to analyze the data obtained. 
 
3.7. Immunofluorescence 
Immunofluorescence is a microscope-based technique used to detect specific target antigens by 
using antibodies labelled with fluorochromes. In this thesis indirect immunofluorescence was 
performed, in which a primary unlabeled antibody binds to the target and then this is recognized by the 
secondary antibody that is fluorophore-labeled.74 
Cells were plated in µ-slide 8 well (80826, ibidi), previously coated with poly-lysine (L7240, 
Biochrom). After 6 h incubation with the experimental conditions, cells were fixed in 2% (w/v) 
paraformaldehyde (104003, Merck Millipore) for 15 min at 4ºC, blocked with 0.1% PBS-BSA / 0.1% 
Triton X-100 for 30 min at room temperature and incubated overnight with primary antibody (diluted 
in 0.1% (w/v) PBS-BSA). The antibodies used were from Endothelial cell characterization kit (SRC023, 
Millipore; anti-ICAM (1:500), anti-VCAM (1:500), anti-CD146 (1:500), anti-vWF (Abcam, 1:5000). 
 After washing with PBS 1X, cells were incubated with the secondary antibodies for 2 h, at 
room temperature. The secondary antibodies (diluted in 0.1% (w/v) PBS-BSA, 1:1000) used were: 
Alexa Fluor 488 goat anti-mouse (115-545-003, Thermo fisher scientific), Alexa Fluor 594 donkey anti-
mouse (A21203, Thermo fisher scientific) and Alexa Fluor 594 goat anti-rabbit (ab150080, Abcam). In 
this technique a negative control is necessary to confirm the specificity of the secondary antibody, being 
stained without primary antibodies. After washing with PBS, all samples were stained with 
VECTASHIELD media with DAPI (4′-6-diamidino-2-phenylindole; Vector Labs), which stains the 
nucleus. Images were acquired in an Olympus IX53 Inverted Microscope and analyzed with ImageJ 
software. 
 
3.8. Rat aortic rings sprouting assay 
The rat aortic ring sprouting assay is an ex vivo assay that consists in the grow of angiogenic 
vessels from a segment of a rat aorta (ring).75 This is a useful procedure to study the sprouting 
angiogenesis, being more functionally relevant than other in vitro assays. 76,77 
Aortas (thoracic and abdominal segments) were dissected from rats and then cleaned to remove 
external tissue and flush off blood from the lumen. After removing all extraneous fat and fibrotic tissue 
and branching vessels, the aorta was segmented into rings with approximately 1 mm. The rings were 
transferred to a Petri dish and incubated overnight in FBS-free culture medium at 37°C, 5% CO2. The 
next day rings were embedded in matrigel (supplemented with the experimental conditions) in a 24-well 
plate and fed with EBM-2 supplemented with the experimental conditions. The medium was replaced 
every 3-4 days and the sprout is visible at 7-10 days. Representative images were acquired at day 10 on 
the Olympus IX53 Inverted Microscope and were analyzed by ImageJ software. The sprouting 
11 
 
quantification was performed by counting the number of branch points per sprouting area (area around 
and inside the ring were sprouting was visible), which is the cell network density, that was then 
normalized to the respective control, obtaining the branch points density. 
 
3.9. Statistical analysis 
All results were analyzed by GraphPad Prism 7.00 software (www.graphpad.com/), using 
student’s t test, one-way ANOVA or two-way ANOVA to evaluate the statistical significance of results. 
The assays were performed with, at least, 3 replicates per condition and the differences were considered 
statistically significant at p < 0.05. 
 
 
 
 
4. Results 
4.1. Metabolic remodeling of endothelial cells upon hypoxia 
To understand the effect of hypoxia on endothelial cells metabolism, NMR spectroscopy was 
performed. For this assay HUVECs were exposed to 12C-glucose, 13C-glucose (9% 13C-glucose + 91% 
12C-glucose) and 13C-lactate (20% 13C-lactate + 80% 12C-lactate), in the presence and absence of hypoxia 
(mimicked by CoCl2). First, we analyzed the supernatants and observed that the cells consumed low 
levels of glucose, probably due to the short time of incubation. Comparing the samples in normoxia 
versus hypoxia there was a decreased concentration of lactate in hypoxia, which is represented in the 
13C spectrum of cells exposed to 13C-lactate (Figure 4. 1 A), showing a decrease of around 10%. 
Moreover, a difference in the histidine peaks was also noticed but it was an interference due to CoCl2, 
given that Co2+ binds to this amino acid, which reflects in a decreased signal of free histidine in hypoxia. 
It was also noticed a difference in the 2-hydroxyisobutyrate peak, being decreased in hypoxia 
represented in the 1H spectrum of cells exposed to 12C-glucose (Figure 4. 1 B).  
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Figure 4. 1 – NMR analysis of supernatants. (A) Regions from the 13C spectrum of supernatants of cells exposed to 13C-
lactate in normoxia (black line) and CoCl2-induced hypoxia (green line). The amplified peaks correspond to the third position 
of lactate. (B) Spectral region from the 1D 1H NOESY experiment from 12C-glucose cell supernatants in normoxia (black) 
versus hypoxia (green). The amplified peak corresponds to 2-hydroxyisobutyrate. 
 
Next we analyzed the aqueous phases, containing the intracellular polar and water-soluble 
metabolites. In spite of the low biomass found in the aqueous phase, it was possible to detect an increase 
of formate and a decrease of lactate, acetate and glucose in hypoxia in the 1H spectrum of cells exposed 
to 13C-lactate (Figure 4. 2). Another difference was detected at 3.75 ppm region, a metabolite that was 
also decreased in hypoxia, but it remained unknown since it was not found on the databases. In the case 
of 13C-lactate, only 3.4% of the lactate inside the cell (aqueous phase) was marked, which means that 
the intracellular lactate enters the cells, but it is also originated from other compounds.  
 
Figure 4. 2 – NMR analysis of the aqueous phases. Regions from the 1D 1H NOESY spectrum of intracellular content of 
cells exposed to 13C-lactate in normoxia (black line) and CoCl2-induced hypoxia (green line). The amplified peaks correspond 
to formate, glucose, the unknown metabolite, acetate and lactate (left to right). 
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4.2. Influence of hypoxia in endothelial activation and vessel-like structures 
formation 
To disclose the effect of hypoxia on tumor angiogenesis, in vitro tube forming assays were 
performed. HUVECs were exposed to 100 μM CoCl2 (to mimic hypoxia) and added to matrigel-
precoated plates for 6 h. These cells were cultured in two different supplemented media: a basal medium, 
only supplemented with FBS, and a pro-angiogenic medium, also supplemented with LSGS (a low 
serum with growth factors) and bFGF. Calcein-labeled HUVECs (Figure 4. 3 A) were observed after 6 
h. CoCl2 exposition increased the number of branch points in both media (Figure 4. 3 B) comparing to 
the control (normoxia), even though the tube length mean didn’t differ between treatments (Figure 4. 3 
C). This suggest that hypoxia might potentiate the formation of vessel-like structures. 
To confirm this result we performed an aortic ring assay, which is an ex vivo assay that consists 
in vessels sprouting from a segment of a rat aorta. The rings were embedded into matrigel and exposed 
to CoCl2 (present both in the medium and in the matrigel). Representative images of day 10 (Figure 4. 
3 D) showed an inhibition of sprouting, which was confirmed by the decrease of branch points density 
normalized to the control (Figure 4. 3 E). This result contradicts the previous in vivo assay and what is 
described in the literature, since hypoxia was reported to potentiate angiogenesis. 
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Figure 4. 3 – Effect of hypoxia on the formation of vessel-like structures and sprouting. (A) Representative images (40 x, 
scale: 200 μm) of the vessel-like structures formed by calcein-labeled HUVECs. Cells were exposed to CoCl2 and cultured in 
basal or pro-angiogenic medium. Quantification of the respective branch points (B) and tube length (C) of the newly-formed 
vessel-like structures. All data are represented as mean ± SD. (*) p<0.05, Two-way ANOVA; (#) p<0.05, Unpaired t-test. (D) 
Representative images of aortic rings at day 10 (40x, scale: 200 μm) (E) Sprouting quantification: number of branch points per 
sprouting area (area around and inside the ring were sprouting was visible), normalized to the control. Results are represented 
as mean ± SD. ****p<0.0001; unpaired t-test (two-tailed). 
 
ECs migration is a key process during sprouting angiogenesis. Therefore, we performed a 
wound healing assay, where HUVECs were exposed to CoCl2 for 24 h (Figure 4. 4 A). There was a 
tendency to a decreased wound closure in ECs exposed to CoCl2 comparing to the control (most noticed 
at 4 h and 6 h), although at the end of the assay the wound had closed (Figure 4. 4 B). Once again, this 
result goes against what is previously described, since hypoxia should have increased EC migration. 
 
 
 
 
 
 
 
Figure 4. 4 – Hypoxia don’t affect endothelial cells 
migration. (A) Representative microscope images (40 x, scale: 
200 μm) of the wound closure evolution through 24 hours. 
HUVECs were exposed to CoCl2 to mimic hypoxia. (B) 
Quantitative analysis of the wound closure. Results are 
represented as mean ± SD. No statistical differences were 
observed between treatments. 
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4.3. Effect of cysteine in endothelial activation under normoxia and hypoxia 
Since Cys is a ROS scavenger important for the maintenance of redox equilibrium and high 
levels of ROS can be promoters of endothelial activation, we wanted to know the role of Cys in this 
process, under normoxia and hypoxia. Therefore, we performed an aortic ring sprouting assay (Figure 
4. 5), in which segments from a rat aorta were exposed to Cys in normoxic and hypoxic conditions. 
There was a tendency to an increase of branch points density (Figure 4. 5 B), whether in normoxia or 
hypoxia. Moreover, the sprouting decreased when cells were exposed to Cys under hypoxia 
comparatively to normoxia. We also tested the effect of H2O2 (ROS), which induced more aortic ring 
sprouting comparing to the control. Rings exposed to Cys and H2O2 seemed to decrease the branch 
points density comparing to H2O2 (not statistically significant) towards a similar level than rings exposed 
to Cys. 
 
 
 
Figure 4. 5 – Cystine effect on aortic ring sprouting. (A) Representative images of rat aortic rings at day 10 (40x, scale: 200 
μm). The rat aorta segments were exposed to cysteine and H2O2 under normoxic and/or hypoxic conditions. (B) Sprouting 
quantification: number of branch points per sprouting area (area around and inside the ring were sprouting was visible), 
normalized to the control. Results are represented as mean ± SD. *p<0.05, ***p<0.001, ****p<0.0001; unpaired t-test (two-
tailed). 
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Next, we performed a wound healing assay to determine the effect of Cys on endothelial cells 
migration. In Figure 4. 6, Cys didn’t have an effect on cell migration. Cells under hypoxia with or 
without Cys had a smaller percentage of wound closure (most noticed at 6 h, Figure 4. 6 B) comparing 
to normoxia, without Cys influence. Moreover, H2O2 exposition didn’t affect cell migration, whether in 
the presence or absence of Cys. 
 
 
      
 
Figure 4. 6 – Cysteine doesn’t affect endothelial cells migration. (A) Representative microscope images (40 x, scale: 200 
μm) of the wound closure evolution at 0h, 2h, 4h, 6h and 24h. HUVECs were exposed to cysteine under normoxia and hypoxia 
conditions and H2O2. (B) Quantitative analysis of the percentage of wound closure. Results are represented as mean ± SD. 
*p<0.05, **p<0.01. (*) statistical analysis in relation to the control; (#) statistical analysis in relation to Cys. 
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4.4. Effect of propranolol in the formation of vessel-like structures 
Since propranolol (P) promotes the regression of infantile hemangiomas by vasoconstriction, 
we started to study its effect on endothelial cell angiogenesis, by performing a tube forming assay 
(Figure 4. 7 and 8). HUVECs were added into matrigel-precoated plates and then exposed to 100 μM 
propranolol and 15 μM H2O2 (to stimulate angiogenesis) for 6 h. Cells were also exposed to two different 
supplemented media: a basal and a pro-angiogenic medium. 
Starting with basal medium (Figure 4. 7), the tube forming images obtained (A) showed that 
propranolol inhibited the formation of vessel-like structures and disrupted the already formed structures 
when added after 4 h (2 h of exposition, referred as Propranolol (2 h)). There was also a significant 
decrease in the number of branch points (B) and tube length (C) with propranolol comparing to the 
control. The number of branch points and tube length are two factors that help in the estimation of the 
extension of tube formation. Moreover, when propranolol was added after 4 h there was a significant 
decrease of number of branch points and tube length mean at 6 h.   
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Figure 4. 7 – Propranolol (P) inhibits the formation of vessel-like structures by HUVECs cultured in basal medium.  
(A) Representative microscope images (40 x, scale: 200 μm) of the vessel-like structures formed by HUVECs after 4h and 
6h. The number of branch points per area (B) and the tube length (C) were quantified in images from the whole well (40 x) 
under the microscope. All data are represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
In the case of the pro-angiogenic medium (Figure 4. 8) it is visible that the net formed is wider 
than the one formed when cultured in basal medium. Similar to the last figure, propranolol disrupted 
most of the structures already formed and inhibited the formation of new vessel-like structures, which 
reflected in the decreasing number of branch points (Figure 4. 8 B) and tube length (Figure 4. 8 C) 
comparing to the control.  
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Figure 4. 8 – Propranolol inhibits the formation of vessel-like structures by HUVECs cultured in pro-angiogenic 
medium. (A) Representative microscope images (40 x, scale: 200 μm) of the vessel-like structures formed by HUVECs after 
4h and 6h. The number of branch points per area (B) and the tube length (C) were quantified in images from the whole well 
(40 x) under the microscope. All data are represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
4.5. Propranolol effect on cell viability 
To determine if propranolol had an effect on endothelial cells viability, a cell death analysis by 
flow cytometry was performed. In Figure 4. 9 the percentage of total cell death of HUVECs was not 
affected by propranolol, whether it was 2 h or 6 h of exposition. Moreover, the percentage of cell death 
due to necrosis, early and late apoptosis didn’t present any differences between treatments 
(Supplementary Figure 1). Therefore, propranolol disrupts angiogenesis without compromising cell 
viability.  
 
 
 
 
 
Figure 4. 9 – Propranolol don’t affect cell viability. Cells were 
exposed for 6h to H2O2, Propranolol (for the last 2h and for the 
whole 6h) with or without H2O2. Results are shown as mean ± SD. 
No statistical differences were observed between treatments. 
 
 
4.6. Effect of propranolol on endothelial cell migration 
The migration of endothelial cells is a crucial step during angiogenesis. In order to investigate 
the in vitro effects of propranolol in endothelial cells migration, a wound healing assay was carried out 
over 24 hours and monitored at the following timepoints: 0, 2, 4, 6, 8, 10 and 24 h. Both control and 
cells exposed to H2O2 were able to completely close the wound, whereas cells exposed to propranolol 
were incapable of complete the wound closure at 24h (Figure 4. 10 A and C). Cells exposed to 
propranolol for less time (propranolol was only added in the last 4 h) had a similar wound closure range 
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of control and H2O2 until the addition of propranolol, which promoted a decrease of the motility (Figure 
4. 10 B). Therefore, propranolol inhibits the two-dimensional migration accessed by this assay. 
 
    
Figure 4. 10 – Propranolol inhibits migration of endothelial cells. (A) Representative microscope images (40 x, scale: 200 
μm) of the wound closure evolution through 24 hours. HUVECs were exposed to H2O2 and propranolol with and without H2O2. 
(B) Quantitative analysis of the wound closure. (C) Quantitative analysis of the wound closure of only control, H2O2, 
propranolol and H2O2+propranolol. All results are represented as mean ± SD. *p<0.05, **p<0.01. (*) statistical analysis in 
relation to the control; (#) statistical analysis in relation to H2O2. 
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4.7. Effect of propranolol on transwell migration 
To further evaluate the directional migratory ability of HUVECs when exposed to propranolol, 
we performed a transwell migration assay. This technique allows the analysis of the ability of a single 
cell to migrate towards the bottom chamber, that is loaded with medium with serum in different 
conditions. Contrarily to the wound healing assay, we found no difference on cell transwell migration 
between treatments (Figure 4. 11). 
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Figure 4. 11 – Propranolol don’t affect transwell migration. (A) Representative images of HUVECs subjected to the 
transwell migration assay with the lower chamber loaded with serum-supplemented medium with the conditions. Top row: 
magnifier images of the transwell (10x, scale: 1 mm). Bottom row: microscopic images (100x, scale: 100 μm). (B) Graphical 
representation of the migrated cells. Results are shown as mean ± SD. No statistical differences were observed between 
treatments. 
 
 
4.8. Impact of Propranolol in ECs markers expression  
To investigate if propranolol interferes with the expression of endothelial cell markers, an 
immunofluorescence staining was performed. 
First, we analyzed the expression of two cell adhesion molecules (CAMs): ICAM (intercellular 
adhesion molecule, CD54) and VCAM (vascular cell adhesion molecule, CD106). ICAM is 
constitutively present on ECs while VCAM is weakly expressed,78 although proinflammatory cytokines 
such as TNFα lead to an upregulation of both adhesion molecules.79,80 These molecules are crucial for 
the leukocyte transendothelial migration out of blood vessels.78 In Figure 4. 12, both molecules presented 
the same expression dynamic. H2O2 and P (2 h) stimulated an upregulation of these molecules (Figure 
4. 12 B).  
Furthermore, we analyzed the expression of CD146 and vWF, two EC markers. CD146 is also 
a CAM, involved in cell-cell adhesions.81 Besides, vWF (von Willebrand factor) has a principal role in 
hemostasis.82 In Figure 4. 13 B, Propranolol downregulated the CD146 expression, while P (2 h) 
upregulated. In the case of vWF (Figure 4. 13 C) there was also a tendency to downregulation when 
exposed to propranolol. 
On all four EC markers, a shorter exposition to propranolol induced an upregulation of the 
respective marker, while propranolol for the whole 6h had the opposite effect. This could indicate that 
the expression of these EC markers is affected by propranolol in a time-dependent manner. 
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Figure 4. 12 – ICAM and VCAM expression in HUVECs. (A) Immunofluorescence images (amplification 400x). Cell nuclei 
were stained with DAPI (blue), ICAM expression is indicated by green fluorescence, red fluorescence is VCAM, and the merge 
of ICAM and VCAM as yellow. (B) Quantification of ICAM and (C) VCAM expression by CTCF (corrected total cell 
fluorescence). All data are represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 4. 13 – CD146 and vWF expression in HUVECs. (A) Immunofluorescence images (amplification 400x). Cell nuclei 
were stained with DAPI (blue), CD146 expression is indicated by green fluorescence, red fluorescence is vWF, and the merge 
as yellow. (B) Quantification of CD146 and (C) vWF expression by CTCF (corrected total cell fluorescence). All data are 
represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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4.9. Effect of propranolol in ex vivo sprouting 
In order to diminish the bridge between in vitro and in vivo studies, the aortic ring assay emerged 
as an ex vivo technique to analyze angiogenesis. The aortic rings were embedded in matrigel and exposed 
to propranolol, H2O2 and the combination of both (Figure 4. 14). H2O2 induced more sprouting 
comparing to the control, forming vessel-like structures (Figure 4. 14 A), which reflected in an increase 
of the branch points density (Figure 4. 14 B). On the contrary, propranolol impeded sprouting, in the 
presence or absence of H2O2, which corroborated the previous results obtained in vitro. 
 
 
 
 
 
Figure 4. 14 – Propranolol inibits aortic ring sprouting. (A) Representative images of aortic rings embedded in matrigel 
(40x, scale: 200 μm) (B) Sprouting quantification: number of branch points per sprouting area (area around and inside the ring 
were sprouting was visible), normalized to the control. Results are represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001; unpaired t-test (two-tailed). 
 
4.10. Metabolic remodeling of endothelial cells – ex vivo model 
In order to understand the metabolic remodeling involved during sprouting, aortic rings were 
collected after the sprouting assay.  Then, we performed an NMR analysis of the rings exposed to the 
conditions mentioned in this thesis: CoCl2, cysteine (Cys), CoCl2 + Cys, H2O2, propranolol (P) and 
H2O2+P. In Figure 4. 15 are the metabolites found in at least three conditions. 
In this set are metabolites connected by metabolic pathways. For instance, isoleucine, leucine 
and valine (A) are amino acids belonging to the same biosynthesis and degradation pathways. These 
metabolites were in higher levels in rings exposed to propranolol (P) and H2O2+P comparing to the 
control, being the levels of leucine and valine in H2O2+P superior to the ones found in propranolol and 
H2O2 exposed rings. While isoleucine and leucine were absent in the hypoxia spectrum, valine was 
present in hypoxia but not in normoxia. 3-hydroxyisovalerate (H) is also present in this pathway, 
downstream leucine. Similar to valine, this metabolite presented higher levels in hypoxia comparing to 
normoxia. Cys and H2O2+P also induced a higher level of 3-hydroxyisovalerate, comparing to the 
control. Glutamine (A) and the previous amino acids are associated to aminoacyl-tRNA biosynthesis, a 
major pathway during translation. Similarly, P and H2O2+P exposition resulted in an increased level of 
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glutamine. This suggests that propranolol might induce the expression of these molecules to increase 
translation. 
There are metabolites involved in pyruvate metabolism: formate (B), acetate (C) and lactate 
(D). Rings exposed to Cys had increased levels of these metabolites comparing with the control. 
However, rings exposed to CoCl2+Cys had higher levels of formate and acetate comparing to the control, 
CoCl2 and Cys. Regarding propranolol, only lactate was increased comparing to the control. Besides, 
the rings exposed to H2O2+P had higher levels of formate and acetate comparing to control, H2O2 and 
propranolol, while lactate had a decreased expression in H2O2+P comparing to these conditions.  
Acetate (C), lactate (D) and glucose (E) are integrated in the glycolysis and gluconeogenesis 
pathways. Referring to glycolysis, glucose is upstream, while lactate and acetate are downstream of 
pyruvate. Glucose wasn’t detected in CTL, CoCl2, Cys and H2O2, yet it was observed an increased level 
on H2O2+P exposed ring comparing to propranolol. The absence of glucose and presence of lactate and 
acetate may indicate an induction of glycolysis in rings exposed to Cys, CoCl2 and H2O2. 
Formate (B) and glycolate (G) belong to glyoxylate and dicarboxylate metabolism, being 
glycolate upstream and formate downstream of glyoxylate. In the case of formate, Cys exposed rings 
presented lower levels than CoCl2+Cys, while the glycolate dynamic was the opposite. Both propranolol 
and H2O2 decreased the expression of glycolate and formate. 
The remaining metabolites were not included in the mentioned pathways. Choline (J) is 
integrated in glycine, serine and threonine metabolism and presented higher levels in aortic rings 
exposed to Cys and propranolol. Pyroglutamate (F) is integrated in GSH metabolism, such as Cys. This 
metabolite reached higher levels in CoCl2, P and H2O2+P. At last, dimethylamine (I) belongs to carbon 
and also methane metabolism, reaching lower levels than the control in all conditions. 
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Figure 4. 15 – Metabolites from aortic rings identified by NMR analysis. The aortic rings were collected after the sprouting 
assay and analyzed by NMR. Metabolites found: (A) Amino acids: isoleucine, leucine, valine and glutamine; (B) formate; (C) 
acetate; (D) lactate; (E) glucose; (F) pyroglutamate; (G) glycolate; (H) 3-hydroxyisovalerate; (I) dimethylamine and (J) 
choline. Y axis: nanomoles per mg of ring tissue. 
 
 
5. Discussion 
It is stated that the tumor microenvironment promotes angiogenesis, in order to satisfy the 
cancer cells’ needs.17,83 Pro-angiogenic molecules are mainly produced by tumor cells, which modulate 
ECs metabolism.84 When rapid tumor growth occurs, the blood supply becomes insufficient leading to 
a hypoxic tumor microenvironment. The oxygen deprivation stimulates the stabilization of the 
transcription factor HIF-1α,52 promoting the activation of pro-angiogenic genes, such as VEGF.12 
Since hypoxia has a high impact in angiogenesis, the first objective of the present work was to 
disclose the role of hypoxia in the metabolic remodeling during the endothelial cell activation. Hence, 
we first verify the impact of hypoxia mimicked by CoCl2 in EC metabolism by NMR. We found that 
lactate levels were decreased in hypoxia both in the extra- and intracellular milieu (Figure 4. 1 A and 
Figure 4. 2), comparing to normoxia. Lactate is known to act as a pro-angiogenic molecule by interfering 
with PHD 2, thus activating HIF-1α, or by activation of the NF-kB pathway.85 Regardless, it was 
expected that the extracellular lactate levels were higher in hypoxia, since hypoxia upregulate glycolysis 
and consequently the secretion of lactate.86 Moreover, 2-hydroxyisobutyrate was found in higher levels 
in the supernatant of cells cultured in hypoxia (Figure 4. 1 B). This metabolite is associated with the 
valine, leucine and isoleucine degradation pathway.87 The increase of intracellular formate levels in 
hypoxia (Figure 4. 2) may reveal a proliferating phenotype, since formate is involved in the purine 
synthesis on proliferating cells, contributing to the one carbon metabolism demand.88 Comparatively, 
the intracellular levels of glucose, lactate and acetate decreased (Figure 4. 2), which may indicate an 
energy production by oxidative phosphorylation, since they all can be precursors of pyruvate. Therefore, 
the data obtained seems to indicate a proliferative phenotype of cells exposed to hypoxia, although it’s 
necessary to repeat this assay to validate this result. Nevertheless, the low exposure time and low 
concentration of 13C-glucose may have contributed to the overall low resonance signal obtained. 
Concerning endothelial activation, we exposed HUVECs to CoCl2 and found that hypoxia 
increased the number of branch points, thus promoting the formation of vessel-like structures (Figure 4. 
3 A-C). This is in accordance with the information found in the literature, since hypoxia is known to 
stimulate angiogenesis. However, the ex vivo rat aortic rings exposed to CoCl2 presented an inhibition 
of sprouting comparing to normoxia (Figure 4. 3 D-E). Also, HUVECs exposed to CoCl2 had a decreased 
wound closure percentage comparing to the control (Figure 4. 4). This make us question if the 
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concentration of CoCl2 used is actually mimicking hypoxia. Despite chemically CoCl2 reacts with 
oxygen impairing its dissolution and oxygenation of aqueous solutions,89 CoCl2 also stabilizes HIF-1α, 
by interfering with the activity of PHDs.90 Cobalt is known as a hypoxia mimicking agent both in vivo91 
and in cell culture, altering several systemic mechanisms related to hypoxia92–94, namely the 
stimulation54 and stabilization of HIF-1α, thus preventing its degradation.95 Although it is widely used 
in cellular experiments due to its low-cost and no special culture and handle conditions, there are some 
limitations in this model. Results from high density oligonucleotide arrays performed on Hep3B cell 
line (hepatocellular carcinoma) showed that CoCl2-induced hypoxia promoted the transcription of gene 
sets that were not affected by low oxygen-induced hypoxia (1% O2).96 Besides, Chandel et al. showed 
that CoCl2 also stimulated ROS generation via a mitochondria-independent mechanism, which in turn 
leads to the activation of HIF-1-dependent transcription. However, this implies that pathways not related 
to hypoxia can be activated by the ROS produced.97 Under these circumstances, CoCl2 needs to be 
further analyzed because it can reproduce some of the effects generated by oxygen deprivation. 
Moreover, a study from Aplin et al. showed that aortic rings cultured in collagen gels under a reduction 
of  O2 levels (1-4%) resulted in inhibition of the angiogenic sprout, since hypoxia caused aortic rings to 
become unresponsive to exogenous VEGF.98 This explains the differences observed in the in vitro and 
ex vivo studies. 
Recently our team showed the relevance of thiols (including Cys) in cancer cell remodeling and 
chemoresistance.53,54 Cys is one component of GSH, an important ROS scavenger for the maintenance 
of redox equilibrium,99 which have being pointed as an inhibitor of angiogenesis.100 Since ROS act as 
pro-angiogenic molecules, we had the intent to investigate the effect of Cys in endothelial activation. 
Although Cys didn’t affect in vitro migration (Figure 4. 6), there was a tendency for a sprouting increase 
in the ex vivo aortic rings (Figure 4. 5), whether in normoxia or hypoxia. Also, HUVECs exposed to Cys 
and H2O2 (ROS) had the same wound closure range of control (Figure 4. 6 C). However, aortic rings 
exposed to H2O2 presented a higher branch points density comparing to control, but these levels 
decreased when Cys was added. This suggests that ROS may play a role in inducing angiogenesis, being 
this effect reverted when Cys is added. As a ROS scavenger, Cys leads to a decrease of free H2O2, 
inhibiting ROS-induced angiogenesis. Other studies also corroborate that antioxidants, including thiols, 
decrease the angiogenic rate (reviewed by Radomska-Leśniewska et al.101). Kubota et al. investigated 
the angiogenic response after alkali injury of the cornea, showing that pretreatment with NAC (N-acetyl-
L-Cys) significantly reduced corneal angiogenesis by downregulating the NF-kB pathway in both SOD-
1-deficient and wild-type mice.102 In another study by Agarwal et al., NAC therapy in athymic nude 
mice with MDA-MB-435 xenografts induced endothelial cell apoptosis and reduction of microvascular 
density, leading to tumor cell apoptosis.103 
In the last years propranolol, a non-selective β-blocker, was applied to hemangiomas treatment. 
This drug was used for symptoms like hypertension, myocardial alterations or migraine and was 
accidentally discovered104 to be a promising treatment for infantile hemangioma (IH), mainly treated 
with corticosteroids. Since then, several studies have shown the regression of IH tumors after 
propranolol treatment, with less adverse effects than corticosteroids.60 Despite its effectiveness, the 
mechanism behind propranolol needs further investigation. Therefore, our next objective was to 
determine the effect of propranolol on angiogenesis. The tube forming assay showed that propranolol 
inhibited the formation of vessel-like structures and disrupted vessel-like structures (Figure 4. 7 and 8). 
We cultured HUVECs in two different mediums, designated basal and pro-angiogenic medium, to 
mimic different tumor microenvironments: one with lower levels of pro-angiogenic molecules and other 
rich in pro-angiogenic molecules. Next we performed a flow cytometry cell death analysis that showed 
that propranolol didn’t affect cell viability (Figure 4. 9), excluding the induction of cell death as a mode 
of action. Regarding migration, a critical event for new vessel sprouting, propranolol inhibited two-
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dimensional migration (Figure 4. 10), whereas the directional migration through a transwell (Figure 4. 
11) was not affected. Lamy et al. showed in a similar assay that propranolol inhibited HUVECs 
migration in a dose-dependent manner.105 Contrarily to our protocol, they added a growth factor-
enriched media 2 h after the cells addition to the upper chamber, to stimulate cell migration.  
To complete our propranolol study in vitro, the expression of some endothelial markers was 
assessed by immunofluorescence (IF). H2O2 and P (2 h) lead to an upregulation of ICAM and VCAM 
(Figure 4. 12), whereas cells exposed to propranolol during the whole exposition time didn’t show a 
differential expression. Which seems that propranolol may abrogate the endothelial activation by ROS, 
but by itself propranolol does not affect the activation of endothelial cells. In the case of CD146 and 
vWF, exposition to propranolol resulted in a downregulated expression, while P (2 h) had the opposite 
effect (Figure 4. 13).  
To close the propranolol chapter, an aortic ring sprouting assay was performed (Figure 4. 14), 
corroborating the result obtained in vitro: propranolol inhibited sprout. However, H2O2 induced 
sprouting of the aortic rings, contrarily to the assays performed in vitro in which it didn’t seem to have 
an effect. As a ROS, H2O2 has a short life inside the cell, which could reflect in the absence of effect in 
the in vitro assays. According to literature ROS are associated with stimulation of angiogenesis. 
Moreover, in the sequence of the work developed by a PhD student from our team, monocytes exposed 
to H2O2 acquire an endothelial phenotype. Importantly, we cannot forget that an aortic ring resumes the 
vessels microenvironment, since it has all the cell types that constitute blood vessels organized in a 
vessel structure. Therefore, the response to sprouting stimuli will be processed in a more efficient way 
by endothelial cells within an aortic ring than by a pure endothelial cell population as HUVECs.  
With the intent to understand the metabolic remodeling involved during sprouting, the rings 
were analyzed by NMR after the sprouting assay (Figure 4. 15). Metabolites were analyzed according 
to the metabolic pathway in which they belong. Isoleucine, leucine and valine are a group of amino 
acids, designated branched-chain amino acids (BCAA). A study showed that BCAA increased eNOS 
expression and ROS production in ECs,106 which shows the importance of these metabolites in the 
angiogenesis context. Moreover, the presence of acetate and lactate and the glucose absence suggest an 
induction of glycolysis in rings exposed to Cys, CoCl2 and H2O2. Stimulation of glycolysis on ECs by 
hypoxia was also showed by Cantelmo et al.. They isolated endothelial cells from mice livers with 
tumors originated by B16-F10 melanoma cells and used liquid chromatography-mass spectrometry (LC-
MS) , showing that hypoxia increased glycolysis.107 Additionally, formate and glycolate belong to 
glyoxylate and dicarboxylate metabolism and while higher levels of formate were observed in 
CoCl2+Cys exposed rings, higher levels of glyoxylate were observed upon exposure to Cys. 
Nevertheless, these results correspond to rings of a single individual. Currently, more samples from 
different animals are being analyzed.  
 
5.1. Main conclusions 
In this thesis we showed that hypoxia alters metabolic pathways that can be important to tumor 
angiogenesis, giving some insights of what happens in the tumor microenvironment. Moreover, we 
analyzed the role of Cys in endothelial activation, showing ex vivo that it can be a promising strategy to 
disturb angiogenesis. Finally, we determined the effect of propranolol in vitro and ex vivo, suggesting it 
can be a potential therapeutic agent for tumor angiogenesis, although it needs to be better studied in this 
context.  
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5.2. Future perspectives  
• To test different hypoxic conditions as different concentrations of CoCl2 and a hypoxia culture 
chamber to decide which is the most advantageous model. Also, compare the metabolic profiles. 
• To verify the role of ROS scavenging in angiogenesis, in order to determine if an anti-ROS 
therapeutic strategy would be worthy to test in order to disturb angiogenesis. 
• To study in depth the propranolol mechanism of action in angiogenesis inhibition, in order to 
determine whether b1 or b2 adrenergic receptors are involved and which signaling pathways can 
be further activated in this inhibitory process. 
• To test the effect of propranolol in vivo using a plug assay with HUVECs and in cancer murine 
xenograft models to unravel the role in tumor neo-vasculature. 
• Testing nanoparticles loaded with β-blockers targeting endothelial cells (in vitro and in vivo). 
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7. Appendices  
 
Solutions prepared during the experimental work: 
 
10X PBS (pH 7.4-7.6) 
For 1 L: 
80g NaCl (1.37M) (106404, Merck) 
2g KH2PO4 (14.7mM) (104873, Merck) 
11.1g Na2HPO4 (78.1mM) (S-0876, Sigma) 
2g KCl (26.8mM) (104936, Merck) 
ddH2O to 1L 
 
50 μg/mL Propidium Iodide (PI) solution 
For 50 mL: 
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS) 
49 mL 1X PBS 
 
Annexin binding buffer 1X 
0.01 M Hepes (pH 7.4) (391333, Millipore) 
0.14 M NaCl (106404, Merck) 
2.5 mM CaCl2 (449709, Sigma) 
 
PBS 0.1% (w/v) BSA 
0.1g BSA (A9647, Sigma) 
100 mL 1X PBS 
 
Crystal violet staining solution 
For 100 mL: 
10 mL of a crystal violet solution 5% 
25 mL methanol 
65 mL ddH2O 
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Supplementary Figure 1 – Propranolol don’t affect cell viability. Cells were exposed for 6h to H2O2, Propranolol (for the 
last 2h and for the whole 6h) with or without H2O2. Results are shown as mean ± SD. No statistical differences were observed 
in early, late apoptosis or necrosis between treatments. 
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